Total Payments
$118,413
2024 Payments
$226.45
Companies
40
Transactions
340
Medicare Patients
1,771
Medicare Billing
$191,017
Payment Breakdown by Category
Other$102,650 (86.7%)
Food & Beverage$7,460 (6.3%)
Travel$7,426 (6.3%)
Consulting$810.00 (0.7%)
Gifts$53.32 (0.0%)
Education$14.50 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $97,750 | 43 | 82.6% |
| Food and Beverage | $7,460 | 232 | 6.3% |
| Travel and Lodging | $7,426 | 61 | 6.3% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $4,900 | 1 | 4.1% |
| Consulting Fee | $810.00 | 1 | 0.7% |
| Gift | $53.32 | 1 | 0.0% |
| Education | $14.50 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $86,630 | 96 | $0 (2023) |
| Allergan, Inc. | $22,474 | 67 | $0 (2020) |
| Valeant Pharmaceuticals North America LLC | $5,235 | 19 | $0 (2017) |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,189 | 10 | $0 (2023) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $335.32 | 17 | $0 (2023) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $227.05 | 17 | $0 (2022) |
| Lilly USA, LLC | $226.64 | 4 | $0 (2024) |
| Celgene Corporation | $192.65 | 16 | $0 (2023) |
| Ironwood Pharmaceuticals, Inc | $160.24 | 9 | $0 (2019) |
| Gilead Sciences, Inc. | $136.41 | 8 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $226.45 | 4 | Regeneron Healthcare Solutions, Inc. ($89.62) |
| 2023 | $698.39 | 34 | Celgene Corporation ($192.65) |
| 2022 | $570.12 | 21 | Takeda Pharmaceuticals U.S.A., Inc. ($168.71) |
| 2021 | $11,384 | 31 | AbbVie Inc. ($10,246) |
| 2020 | $10,553 | 17 | AbbVie Inc. ($10,506) |
| 2019 | $32,030 | 45 | AbbVie, Inc. ($31,344) |
| 2018 | $23,705 | 65 | AbbVie, Inc. ($18,133) |
| 2017 | $39,247 | 123 | Allergan Inc. ($17,202) |
All Payment Transactions
340 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/21/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $31.57 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/27/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $89.62 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/02/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $25.41 | General |
| Category: GASTROENTEROLOGY | ||||||
| 01/19/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | Cash or cash equivalent | $79.85 | General |
| Category: Diabetes | ||||||
| 10/25/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $9.38 | General |
| Category: Neuroscience | ||||||
| 10/16/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $13.34 | General |
| Category: Neuroscience | ||||||
| 10/16/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $1.48 | General |
| Category: Neuroscience | ||||||
| 09/12/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $20.66 | General |
| Category: Neuroscience | ||||||
| 09/11/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $13.34 | General |
| Category: Neuroscience | ||||||
| 08/16/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $21.69 | General |
| Category: NEUROSCIENCE | ||||||
| 07/12/2023 | Takeda Pharmaceuticals U.S.A., Inc. | GATTEX (Drug) | Food and Beverage | In-kind items and services | $29.19 | General |
| Category: INTERNAL MEDICINE | ||||||
| 07/12/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $16.20 | General |
| Category: Neuroscience | ||||||
| 07/07/2023 | Hydrofera LLC | HYDROFERA BLUE (Device) | Food and Beverage | In-kind items and services | $47.12 | General |
| Category: WOUND CARE | ||||||
| 07/01/2023 | ABBVIE INC. | LINZESS (Drug), VIBERZI | Food and Beverage | In-kind items and services | $13.82 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/28/2023 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $122.04 | General |
| Category: Neuroscience | ||||||
| 06/27/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $6.10 | General |
| Category: Neuroscience | ||||||
| 06/26/2023 | Takeda Pharmaceuticals U.S.A., Inc. | GATTEX (Drug) | Food and Beverage | In-kind items and services | $28.13 | General |
| Category: INTERNAL MEDICINE | ||||||
| 06/20/2023 | Fresenius Kabi USA, LLC | — | Food and Beverage | In-kind items and services | $23.20 | General |
| 06/19/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $22.75 | General |
| Category: Neuroscience | ||||||
| 06/13/2023 | INTERCEPT PHARMACEUTICALS, INC. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $17.73 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 06/12/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $14.61 | General |
| Category: Neuroscience | ||||||
| 05/24/2023 | Takeda Pharmaceuticals U.S.A., Inc. | GATTEX (Drug) | Food and Beverage | In-kind items and services | $24.04 | General |
| Category: INTERNAL MEDICINE | ||||||
| 05/23/2023 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $29.17 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 05/16/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $24.03 | General |
| Category: Gastroenterology | ||||||
| 05/08/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $17.23 | General |
| Category: Neuroscience | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 396 | 439 | $314,891 | $45,976 |
| 2022 | 8 | 530 | 602 | $347,814 | $59,352 |
| 2021 | 9 | 445 | 492 | $281,761 | $49,658 |
| 2020 | 10 | 400 | 444 | $168,238 | $36,032 |
Total Patients
1,771
Total Services
1,977
Medicare Billing
$191,017
Procedure Codes
35
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 108 | 149 | $38,633 | $11,534 | 29.9% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 43 | 43 | $82,320 | $10,848 | 13.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 95 | 95 | $30,915 | $8,522 | 27.6% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 57 | 57 | $91,500 | $6,769 | 7.4% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 17 | 17 | $18,428 | $3,252 | 17.6% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 34 | 35 | $45,208 | $2,865 | 6.3% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 19 | 19 | $4,010 | $1,119 | 27.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 23 | 24 | $3,877 | $1,067 | 27.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 154 | 222 | $48,987 | $17,541 | 35.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 171 | 171 | $46,853 | $15,772 | 33.7% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 84 | 84 | $126,040 | $10,729 | 8.5% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 41 | 41 | $76,080 | $10,017 | 13.2% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 35 | 36 | $43,919 | $3,739 | 8.5% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 16 | 16 | $3,370 | $778.37 | 23.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 15 | 16 | $2,149 | $729.35 | 33.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 14 | 16 | $416.00 | $47.16 | 11.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 123 | 170 | $36,555 | $13,788 | 37.7% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 135 | 135 | $36,690 | $12,508 | 34.1% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 66 | 66 | $95,480 | $8,146 | 8.5% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 30 | 30 | $52,640 | $7,336 | 13.9% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2021 | 17 | 17 | $20,009 | $3,738 | 18.7% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 29 | 29 | $34,641 | $2,575 | 7.4% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 19 | 19 | $2,340 | $877.67 | 37.5% |
| 99202 | New patient outpatient visit, total time 15-29 minutes | Office | 2021 | 15 | 15 | $3,155 | $656.60 | 20.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 11 | 11 | $251.00 | $33.00 | 13.1% |
About Dr. Bill Kim, MD
Dr. Bill Kim, MD is a Gastroenterology healthcare provider based in Soldotna, Alaska. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1255438727.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bill Kim, MD has received a total of $118,413 in payments from pharmaceutical and medical device companies, with $226.45 received in 2024. These payments were reported across 340 transactions from 40 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($97,750).
As a Medicare-enrolled provider, Kim has provided services to 1,771 Medicare beneficiaries, totaling 1,977 services with total Medicare billing of $191,017. Data is available for 4 years (2020–2023), covering 35 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Soldotna, AK
- Active Since 09/19/2006
- Last Updated 12/20/2023
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1255438727
Products in Payments
- Creon (Drug) $32,741
- LINZESS (Drug) $21,517
- CREON (Drug) $6,054
- UCERIS (Drug) $5,174
- GATTEX (Drug) $1,123
- VIBERZI (Drug) $1,068
- ZEPOSIA (Drug) $314.69
- LifeVest (Device) $227.05
- MOUNJARO (Drug) $204.85
- XIFAXAN (Drug) $139.61
- OCALIVA (Drug) $126.11
- DUPIXENT (Biological) $114.99
- Sucraid (Drug) $110.74
- RELISTOR ORAL (Drug) $110.42
- SUPREP BOWEL PREP (Drug) $95.56
- PREVNAR - 13 (Biological) $88.17
- XIFAXANIBSD (Drug) $75.55
- SHINGRIX (Biological) $62.15
- IBSRELA (Drug) $56.98
- FLUZONE HIGH-DOSE (Drug) $47.53
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.